A peptide with history
Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated in 1974 by the Swiss group of Schoenenberger and Monnier, who reported that a substance extracted from the cerebral blood of sleeping rabbits could promote delta-wave (slow-wave) EEG activity when infused into recipient animals. Few peptides in the catalogue have a discovery story this old — or this contested.
What the literature covers
- Sleep-architecture studies — the founding line of research measured EEG delta activity in rabbits, rats and cats. Results across decades have been mixed, with some labs replicating the slow-wave effect and others finding none.
- Stress-marker research — a consistent secondary literature examines DSIP's effects on corticotropin and stress-hormone levels in animal models.
- Antioxidant and mitochondrial studies — later Russian work explored membrane-stabilising and antioxidant properties in tissue models.
- The receptor question — remarkably, no specific DSIP receptor has ever been identified, and the native gene encoding it remains unknown. This open question is itself a research topic.
Why DSIP still appears in research
DSIP endures precisely because it is unresolved: a molecule with reproducible bioactivity in some models, no identified receptor, and no confirmed endogenous source. For sleep-biology and neuropeptide labs it remains a genuinely open puzzle. It is sometimes studied alongside other CNS-focused peptides such as Selank and Semax.
Sourcing
DSIP from BioSupply UK is supplied at ≥99% HPLC-verified purity with a Certificate of Analysis, strictly for laboratory research.
Summary
Fifty years after its discovery, DSIP remains one of neuroscience's stranger loose ends — which is exactly what keeps it on research benches. No human clinical evidence supports any therapeutic use.
All products mentioned are supplied strictly for laboratory research purposes only and are not intended for human consumption, diagnosis, or treatment. Nothing in this article constitutes medical advice.